S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

JNJ Johnson and Johnson

144.15

0.13 (0.09%)

Jan 03 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Bradley Camilo, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for William N. Hait

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Thursday 2 January 2025 (3 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Thursday 12 December 2024 (3 weeks ago) • Business Wire

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Tuesday 10 December 2024 (4 weeks ago) • Business Wire

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
Monday 9 December 2024 (4 weeks ago) • PR Newswire (US)

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
Monday 9 December 2024 (4 weeks ago) • PR Newswire (US)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

Form 144 - Report of proposed sale of securities
Wednesday 4 December 2024 (1 month ago) • Edgar (US Regulatory)

More Johnson and Johnson News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions